New drug aims to shield cancer patients from chemo side effects
NCT ID NCT07160283
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether the drug trilaciclib can protect bone marrow in 96 people with advanced bile duct or pancreatic cancer before they receive chemotherapy. The goal is to reduce serious side effects like low white blood cell counts, which can lead to infections. Participants will receive trilaciclib as an IV infusion before their standard chemotherapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Trilaciclib
- What this could lead to
- If it works, this could lead to a way to protect bone marrow during chemotherapy, reducing serious infections and allowing more effective treatment for bile duct and pancreatic cancer.
- What could go wrong
- This is an early phase 2 trial with only 96 participants, so results may not be conclusive. The drug may not reduce side effects significantly, and there could be unknown risks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a vaccine help fight Hard-to-Treat cancers?
- Blood and gut clues may flag pancreatic cancer risk early
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- Can a new imaging trick spot pancreatic cancer without a biopsy?
- MRI might reveal hidden pancreatic risks in obesity
- Can a new PET tracer light up hidden cancers?